D341Med Cells

The D341 Med cell line was established in 1988 by Friedman et al. from tumor tissue extracted from a 3-year-old boy diagnosed with medulloblastoma. Medulloblastoma is a highly malignant pediatric brain tumor predominantly occurring in the cerebellum. This cell line is crucial for research due to its origin from a common type of childhood brain cancer, providing insights into the tumor biology and genetics specific to pediatric cases. D341 Med has been extensively utilized in studies aimed at understanding the molecular and cellular mechanisms of medulloblastoma, including investigations into the genetic mutations and signaling pathways that contribute to tumorigenesis and treatment resistance. In addition to its role in basic research, the D341 Med cell line has been instrumental in preclinical studies assessing new therapeutic approaches for medulloblastoma. Its genetic profile, which reflects common alterations seen in human tumors, makes it an excellent model for evaluating the efficacy of potential drugs and novel therapeutic strategies. The use of D341 Med in these studies helps to bridge the gap between laboratory research and clinical application, supporting the development of targeted therapies that could offer improved outcomes for children affected by this devastating disease.